Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Completed 16Terminated 5Recruiting 5Active not recruiting 4Withdrawn 3Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Genitourinary 1CNS 1

Conditions

Carcinoma, Hepatocellular 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Leiomyosarcoma 1Glioblastoma 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Interventional × ADI PEG20 × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT05712694 2026-04-20

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Polaris Group

Phase 3 Recruiting
300 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

NCT06085729 2026-04-02

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT05317819 2025-12-18

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Polaris Group

Phase 3 Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06034977 2023-09-13

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Chang Gung Memorial Hospital

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡